Yarrow Bioscience Inc. and VYNE Therapeutics Inc. have entered into a definitive merger agreement.
Upon completion of the merger, the combined company plans to operate as Yarrow Bioscience, Inc. and trade on Nasdaq under the ticker symbol YARW.
The merger aims to advance Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (TSHR) antibody for Graves' disease (GD) and thyroid eye disease (TED).
Merger Details
All-stock transaction merging Yarrow Bioscience Inc. and VYNE Therapeutics Inc.
Focus on YB-101
Plan to advance YB-101, a clinical-stage TSHR antibody for GD and TED.
Financial Support
Secured approximately $200 million in pre-closing private financings.
Clinical Trials
Expected Phase 1b/2b trial in GD patients in the U.S. and Phase 1 trial in TED patients in China.
Cash Dividend
Anticipated declaration of cash dividend to pre-Merger VYNE stockholders.
- Yarrow Bioscience to progress lead program YB-101, potentially improving treatment options for GD and TED.
- Merger provides a solid foundation for Yarrow to address unmet needs in autoimmune thyroid disorders.
- Financial support from industry-leading healthcare investors ensures funding till 2028 for operational advancements.
The merger between Yarrow Bioscience Inc. and VYNE Therapeutics Inc. sets a promising path for the development of innovative treatments for Graves' disease and thyroid eye disease, addressing critical unmet medical needs in autoimmune thyroid disorders.